Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches

July 5, 2026

REPROCELL スペイン

Overview

Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. This state-of-the-art unit is designed to support all development phases, from preclinical research to commercial production of cell therapy stocks and cell-derived biologics. The expansion, particularly relevant with technologies like REPROCELL’s hypoimmune iPSCs, promises to accelerate the scalable development of ‘off-the-shelf’ cell therapies.

In Depth

Background

The landscape of cell therapy is undergoing rapid expansion, driven by transformative breakthroughs such as CAR-T cell therapies and induced pluripotent stem cell (iPSC)-derived treatments. Despite this formidable progress, scaling up the manufacturing of these advanced therapies to consistently ensure both high quality and sufficient quantity presents a considerable, multi-faceted challenge. The scarcity of GMP-compliant production facilities and highly specialized expertise frequently creates significant bottlenecks within the development pipeline. Consequently, strategic investments by Contract Development and Manufacturing Organizations (CDMOs) such as Histocell are paramount to surmount these hurdles and accelerate the commercialization of potentially life-changing cell therapies.

Key Findings

Histocell has officially unveiled a significant expansion of its manufacturing capabilities with the commissioning of an 800 m² Advanced Therapies Good Manufacturing Practice (GMP) cell production unit. This state-of-the-art facility is engineered to produce approximately 1,200 batches per year, catering to both autologous (patient-specific) and allogeneic (‘off-the-shelf’) therapies. This substantial increase in capacity directly addresses the escalating demand within the rapidly expanding cell and gene therapy sector. The strategic expansion is meticulously designed to provide comprehensive support across all development phases, spanning preclinical research, clinical trials, and ultimately, commercial-scale manufacturing.

Key technical specifications and enhanced capabilities of the new unit include:

Extensive Manufacturing Versatility: The facility is robustly equipped to handle both autologous cell therapies, which meticulously utilize a patient’s own cells, and allogeneic cell therapies, which strategically leverage cells from healthy donors for broader patient application. This inherent versatility is paramount for supporting a diverse and rapidly expanding pipeline of advanced cell therapy products.
Broad Product Portfolio: Beyond foundational cell therapy stocks, the unit possesses the capability to manufacture sophisticated cell-derived biologics, encompassing therapeutic molecules either extracted from or secreted by cells. This significantly expands its utility and responsiveness to the multifaceted demands of Advanced Therapy Medicinal Products (ATMPs).
Rigorous GMP Compliance: Unwavering adherence to the highest Good Manufacturing Practice (GMP) standards is intrinsically embedded in the facility’s design and operational protocols. This stringent compliance is critical for ensuring the consistent quality, safety, and efficacy of all manufactured cell products, thereby streamlining regulatory approval pathways.
Synergy with REPROCELL’s StemEdit Platform: A particularly significant strategic implication arises from the inherent synergy with complementary technologies such as REPROCELL’s StemEdit platform. This innovative platform specializes in developing ‘hypoimmune iPSCs’ (induced pluripotent stem cells) through advanced gene-editing techniques. These meticulously engineered iPSCs are designed to effectively evade host immune rejection, positioning them as promising universal donor cell sources. Histocell’s significantly expanded manufacturing capacity, when seamlessly coupled with such hypoimmune iPSC technology, transforms the scalable production of ‘off-the-shelf’ allogeneic cell therapies from a theoretical concept into a tangible, accelerated reality.

This strategic expansion by Histocell is poised to significantly accelerate both the clinical development and market accessibility of advanced cell therapy products. An annual production capacity of 1,200 batches not only enables simultaneous support for multiple clinical programs but also ensures a stable and reliable supply for commercialized therapies. The synergistic potential with REPROCELL’s hypoimmune iPSC technology is particularly noteworthy, directly addressing the critical challenge of immune rejection inherent in allogeneic cell therapies. This collaboration promises to contribute substantially to the development of more accessible, effective, and truly ‘off-the-shelf’ cell therapeutics, thereby making groundbreaking treatment options more readily available to patients worldwide.

Source: https://www.reprocell.com/clinical-stem-cell-services/histocell-our-gmp-cell-manufacturing-partner

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.